Cancer research institute. https://www.cancerresearch.org/scientists/immuno-oncology-landscape/fda-approval-timeline-of-active-immunotherapies.
Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614.e14 (2021).
Google Scholar
Aurisicchio, L., Pallocca, M., Ciliberto, G. & Palombo, F. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J. Exp. Clin. Cancer Res. 37, 86 (2018).
Google Scholar
Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081–1091 (2012).
Google Scholar
Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572–576 (2014).
Google Scholar
Duan, F. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211, 2231–2248 (2014).
Google Scholar
Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324–327 (2014).
Google Scholar
Martin, S. D. et al. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. 1–22 (2016) https://doi.org/10.1371/journal.pone.0155189.
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489–496 (2017).
Google Scholar
Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
Google Scholar
Zolkind, P. et al. Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. 9, 4109–4119 (2018).
Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).
Google Scholar
Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).
Google Scholar
Duperret, E. K. et al. A synthetic DNA, multi-neoantigen vaccine drives predominately MHC Class I CD8(+) T-cell responses, impacting tumor challenge. Cancer Immunol. Res. 7, 174–182 (2019).
Google Scholar
Aurisicchio, L. et al. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth. J Exp Clin Cancer Res. 4, 1–13 (2019).
Arbelaez, C. A. et al. OPEN A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses. npj Vaccines 1–14 https://doi.org/10.1038/s41541-020-00253-9.
Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–362.e24 (2020).
Google Scholar
Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Sci. (80-.). 348, 803–808 (2015).
Google Scholar
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
Google Scholar
Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).
Google Scholar
Fang, Y. et al. A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors. Clin. Cancer Res. clincanres. 2881.2019 (2020). https://doi.org/10.1158/1078-0432.ccr-19-2881.
Biernacki, M. A. et al. CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. J. Clin. Invest. 130, 5127–5141 (2020).
Google Scholar
Cafri, G. et al. mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Invest. 130, 5976–5988 (2020).
Google Scholar
Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133.e17 (2017).
Google Scholar
Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473–486 (2016).
Google Scholar
Hailemichael, Y. et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J. Clin. Invest. 128, 1338–1354 (2018).
Google Scholar
Field, C. S. et al. Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model. Oncoimmunology. 7, e1376154 (2018). https://doi.org/10.1080/2162402X.2017.1376154.
Lione, L. et al. Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition. Oncoimmunology. 10, 1898832 (2021).
Castle, J. C. et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 15, 190 (2014).
Google Scholar
Li, A. W., Sobral, M. C., Badrinath, S., Choi, Y. & Graveline, A. A facile approach to enhance antigen response for personalized cancer vaccination. Nat. Mater. 17, 528−534 (2018).
D’Alise, A. M. et al. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat. Commun. 10, 1–12 (2019).
Google Scholar
Tondini, E. et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control cell-mediated tumor control (2019). https://doi.org/10.1080/2162402X.2019.1652539.
Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat. Immunol. https://doi.org/10.1038/s41590-020-00810-3 (2020).
Google Scholar
Capietto, A.-H. et al. Mutation position is an important determinant for predicting cancer neoantigens. J. Exp. Med. 217, e20190179 (2020).
Swartz, A. M. et al. OPEN A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. npj Vaccines https://doi.org/10.1038/s41541-020-00273-5 (2021).
Google Scholar
Salomon, N. et al. A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice. Oncoimmunology 9 (2020).
Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).
Google Scholar
Tondini, E. et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 8, 1652539 (2019).
Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3 þ regulatory T cells (Tregs) in human cancers. 1233–1239 (2019) https://doi.org/10.1158/1078-0432.CCR-18-0762.
Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191–1206.e21 (2019).
Google Scholar
Bhojnagarwala, P. S., Perales-Puchalt, A., Cooch, N., Sardesai, N. Y. & Weiner, D. B. A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation. Mol. Ther. – Oncolytics 21, 278–287 (2021).
Google Scholar
Selby, M. J. et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: Mouse tumor models, In vitro functional studies, and cynomolgus macaque toxicology. PLoS One 11, 1–19 (2016).
Xu, C. et al. Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Red. (2020) https://doi.org/10.1021/acsnano.0c05062.
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 16, 489−496 (2016).
Krummel, B. M. F. & Allison, J. R. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 182, 459–465 (1995).
Ovcinnikovs, V. et al. CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells. Sci. Immunol. 4, eaaw0902 (2019).
Adam, L. et al. Innate molecular and cellular signature in the skin preceding long-lasting T cell responses after electroporated DNA vaccination. J. Immunol. 204, 3375–3388 (2020).
Google Scholar
Todorova, B. et al. Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. 1–11 (2017) https://doi.org/10.1038/s41598-017-04547-2.
Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231–1243 (2019).
Google Scholar
Philip, M. et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545, 452–456 (2017).
Google Scholar
Thibult, M. L. et al. Pd-1 is a novel regulator of human B-cell activation. Int. Immunol. 25, 129–137 (2013).
Google Scholar
Wang, X. et al. PD-1-expressing B cells suppress CD4 + and CD8 + T cells via PD-1/PD-L1-dependent pathway. Mol. Immunol. 109, 20–26 (2019).
Google Scholar
Ahrends, T. et al. CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination. Cancer Res. 76, 2921–2931 (2016).
Google Scholar
Elia, L. et al. CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther. 14, 201–210 (2007).
Google Scholar
Lin, F. et al. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum. Gene Ther. Methods 23, 157–168 (2012).
Google Scholar
